423 related articles for article (PubMed ID: 18284811)
21. Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis.
Ishibashi T; Yano Y; Oguma T
Anticancer Res; 2005; 25(2B):1273-81. PubMed ID: 15865078
[TBL] [Abstract][Full Text] [Related]
22. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?
Viale M; Vannozzi MO; Pastrone I; Mariggiò MA; Zicca A; Cadoni A; Cafaggi S; Tolino G; Lunardi G; Civalleri D; Lindup WE; Esposito M
J Pharmacol Exp Ther; 2000 Jun; 293(3):829-36. PubMed ID: 10869382
[TBL] [Abstract][Full Text] [Related]
23. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE
Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
[TBL] [Abstract][Full Text] [Related]
24. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity.
Thomas JP; Lautermann J; Liedert B; Seiler F; Thomale J
Mol Pharmacol; 2006 Jul; 70(1):23-9. PubMed ID: 16569706
[TBL] [Abstract][Full Text] [Related]
25. Effect of time of cisplatin administration on its toxicity and pharmacokinetics in dogs.
Hardie EM; Page RL; Williams PL; Fischer WD
Am J Vet Res; 1991 Nov; 52(11):1821-5. PubMed ID: 1686160
[TBL] [Abstract][Full Text] [Related]
26. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.
Asna N; Lewy H; Ashkenazi IE; Deutsch V; Peretz H; Inbar M; Ron IG
Life Sci; 2005 Mar; 76(16):1825-34. PubMed ID: 15698860
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow.
Prajda N; Kralovánszky J; Gal F; Kiss F; Kerpel-Fronius S
In Vivo; 1989; 3(4):267-70. PubMed ID: 2519864
[TBL] [Abstract][Full Text] [Related]
28. Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes.
Kim WK; Kwon YE
Cancer Chemother Pharmacol; 2007 Jul; 60(2):237-43. PubMed ID: 17089165
[TBL] [Abstract][Full Text] [Related]
29. Clinical pharmacokinetics of carboplatin.
van der Vijgh WJ
Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and tissue distribution of iv injection of polyphase liposome-encapsulated cisplatin (KM-1) in rats.
Wang S; Mi JB; Li YZ; Chang WB; Ci YX; Zhao MZ; Zhao YK; Zhu LY; Xu G
Acta Pharmacol Sin; 2003 Jun; 24(6):589-92. PubMed ID: 12791187
[TBL] [Abstract][Full Text] [Related]
31. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice.
Boughattas NA; Lévi F; Fournier C; Hecquet B; Lemaigre G; Roulon A; Mathé G; Reinberg A
J Pharmacol Exp Ther; 1990 Nov; 255(2):672-9. PubMed ID: 2243347
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and tissue distribution of novel traditional Chinese medicine-platinum anticancer agents in rats.
Wang X; Au-Yeung SC; Ho YP
J Inorg Biochem; 2007 Jun; 101(6):909-17. PubMed ID: 17428541
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
[TBL] [Abstract][Full Text] [Related]
34. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system.
Stöhr W; Paulides M; Bielack S; Jürgens H; Koscielniak E; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Feb; 48(2):140-7. PubMed ID: 16724313
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of a formula for individual dosage of nedaplatin based on renal function.
Sato S; Fujiwara H; Oishi T; Shimada M; Machida S; Takei Y; Itamochi H; Suzuki M; Kigawa J
Cancer Chemother Pharmacol; 2012 Mar; 69(3):599-603. PubMed ID: 21918903
[TBL] [Abstract][Full Text] [Related]
36. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
37. Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin.
Xing R; Wang X; Zhang C; Zhang Y; Wang Q; Yang Z; Guo Z
J Inorg Biochem; 2009 Jul; 103(7):1039-44. PubMed ID: 19501911
[TBL] [Abstract][Full Text] [Related]
38. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.
van Hennik MB; van der Vijgh WJ; Klein I; Elferink F; Vermorken JB; Winograd B; Pinedo HM
Cancer Res; 1987 Dec; 47(23):6297-301. PubMed ID: 3315183
[TBL] [Abstract][Full Text] [Related]
39. The immediate early genes, c-fos, c-jun and AP-1, are early markers of platinum analogue toxicity in human proximal tubular cell primary cultures.
Wainford RD; Weaver RJ; Hawksworth GM
Toxicol In Vitro; 2009 Aug; 23(5):780-8. PubMed ID: 19383537
[TBL] [Abstract][Full Text] [Related]
40. [Comparative study of the action of antineoplastic platinum compounds with varying nephrotoxic effects].
Bakhteeva VT; Fok EM; Lavrova EA
Vopr Med Khim; 1996; 42(4):301-6. PubMed ID: 9254514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]